ADMA Biologics Files 8-K Report
Ticker: ADMA · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 8-K |
| Filed Date | Mar 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-reporting, regulatory-filing
Related Tickers: ADMA
TL;DR
ADMA Biologics filed a routine 8-K, mostly about exhibits. Nothing major to see here.
AI Summary
On March 11, 2024, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text. The company is incorporated in Delaware and headquartered in Ramsey, New Jersey.
Why It Matters
This 8-K filing indicates that ADMA Biologics is fulfilling its regulatory reporting requirements, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for financial statements and exhibits, indicating routine compliance rather than a significant event.
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — Registrant
- March 11, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Ramsey, New Jersey (location) — Address of principal executive offices
- 001-36728 (identifier) — Commission File Number
- 56-2590442 (identifier) — IRS Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing for ADMA Biologics?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 11, 2024.
In which state is ADMA Biologics, Inc. incorporated?
ADMA Biologics, Inc. is incorporated in Delaware.
What is the principal executive office address for ADMA Biologics, Inc.?
The principal executive office address is 465 State Route 17, Ramsey, New Jersey 07446.
Does this filing indicate any specific material events or changes for ADMA Biologics?
Based on the provided text, the filing is categorized under 'Other Events' and 'Financial Statements and Exhibits,' suggesting a routine reporting rather than a specific material event announcement.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-03-11 16:05:40
Filing Documents
- ef20023792_8k.htm (8-K) — 28KB
- ef20023792_ex99-1.htm (EX-99.1) — 14KB
- image00002.jpg (GRAPHIC) — 5KB
- 0001140361-24-012605.txt ( ) — 185KB
- adma-20240311.xsd (EX-101.SCH) — 4KB
- adma-20240311_lab.xml (EX-101.LAB) — 21KB
- adma-20240311_pre.xml (EX-101.PRE) — 16KB
- ef20023792_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events On March 11, 2024, ADMA Biologics, Inc. (the "Company") issued a press release announcing the United States Food and Drug Administration's approval for the Company's supplemental Biologics License Applications for both ASCENIV and BIVIGAM to extend the approved 4-week room temperature (25C) storage conditions during the first 24 months of shelf life, to allow for a 4-week room temperature storage at any time during the entire 36-month approved shelf life. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference herein.
01
Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 ADMA Biologics, Inc. Press Release, dated March 11, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. March 11, 2024 ADMA Biologics, Inc. By: /s/ Brian Lenz Name: Brian Lenz Title: Executive Vice President and Chief Financial Officer